Engineered immune cells take on tough leukemia in early trial
NCT ID NCT06447987
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial tests a personalized cell therapy for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. Patients' own immune cells are collected, genetically modified to recognize and attack cancer cells, and then infused back after chemotherapy. The study aims to check safety and how well the treatment works in 24 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- humanized CD19-specific CAR T cells
- What this could lead to
- If successful, this could provide a new treatment option for adults with B-cell acute lymphoblastic leukemia that has returned or not responded to prior therapy.
- What could go wrong
- This is an early Phase 1 trial with only 24 participants, so results may not apply broadly. Side effects like cytokine release syndrome or neurotoxicity are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at tough childhood leukemia
- Selective immune cell removal may tame transplant complications
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- New drug combo tested for tough childhood leukemia
- Promising combo targets tough leukemia
- New drug cocktail aims to tackle tough blood cancers